HIV transmission from infected CD4+ T cells to allogenic T and dendritic cells is inhibited by broadly neutralizing antibodies. (19th June 2018)

• Record Type: Journal Article
• Authors: Ducloy, Camille; Su, Bin; Mayr, Luzia; Klingler, Jéromine; Decoville, Thomas; Schmidt, Sylvie; Laumond, Géraldine; Salomé, Nathalie; Bahram, Seiamak; Moog, Christiane
• Is Part Of: AIDS. Volume 32:Number 10(2018)
• Publication Date: 2018-06-19
• Subjects: allogenic T cells -- broadly neutralizing antibodies -- dendritic cells -- HIV cell-to-cell transmission; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000001834
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objective: In the semen, both free virus and infected cells are able to establish HIV infection during sexual intercourse. An efficient vaccine should therefore inhibit both infectious states. The aim of this study was to analyze the capacity of broadly neutralizing antibodies (bNAbs) to inhibit HIV transmission by the infected cells. Design/methods: We developed an in-vitro model aiming to mimic mucosal HIV transmission via infected cells. PHA-activated CD4 + T cells stained with PKH26 from donor A were infected and co-cultured with CD4 + T cells and dendritic cells from donor B in the presence of bNAbs. Results: We showed that dendritic cells were the preferential HIV target cells at early time points in this co-culture model. In the context of this co-culture model where infection and transmission occurred simultaneously, bNAbs efficiently inhibited HIV replication as well as HIV transmission from infected cells to allogenic dendritic cells and CD4 + T cells. Conclusion: Overall, our results indicate that dendritic cells, in addition to CD4 + T cells, are key cells that are efficiently infected by HIV and bNAbs are potent inhibitors of infection of both target cells. Future HIV prophylactic vaccine design should develop immune strategies able to prevent the infection of dendritic cells, in addition to the inhibition of CD4 + T-cell infection.